文献速递免疫规划慢病防控与筛查

多发性硬化患者接受疾病修饰治疗后的COVID mRNA疫苗体液反应特征

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.
PubMed 文献 · Vaccine · 2021-09-02

该单中心前瞻性研究纳入53名多发性硬化(MS)和视神经脊髓炎(NMO)患者,评估COVID-19 mRNA疫苗接种前后抗体反应。使用B细胞耗竭治疗(BCDT)的患者中仅36.4%产生针对刺突RBD的抗体阳性反应,而健康对照、未治疗MS及非B细胞耗竭治疗组均为100%(p<0.0001)。低CD19/CD20计数及距末次BCDT输注至首剂疫苗间隔较短与血清阴性相关。

要点

  • BCDT治疗患者接种mRNA疫苗后仅36.4%出现抗RBD抗体阳性,其他组为100%。
  • 低CD19/CD20计数和较短BCDT输注至接种间隔与抗体阴性相关。
  • 年龄、BMI和治疗总时长在血清阳转与未阳转者间无差异。

核心结论

  • 接受B细胞耗竭治疗的多发性硬化及视神经脊髓炎患者COVID-19 mRNA疫苗体液反应显著受损,仅36.4%产生抗RBD抗体阳性。
  • 低CD19/CD20计数及较短BCDT输注至首剂疫苗间隔与抗体阴性相关。

研究设计与样本

  • 单中心前瞻性研究,纳入53名参与者,在COVID-19 mRNA疫苗接种前后检测抗体反应。
  • 研究对象包括多发性硬化(MS)和视神经脊髓炎(NMO)患者,部分接受B细胞耗竭治疗或其他疾病修饰治疗。
  • 检测抗刺突RBD和抗核衣壳抗体,并分析疫苗接种前后绝对淋巴细胞计数及CD19/CD20流式细胞术。

主要发现

  • BCDT治疗组中36.4%出现抗刺突RBD抗体阳性,而健康对照、未治疗MS及非B细胞耗竭DMT组均为100%(p<0.0001)。
  • BCDT治疗患者基线(疫苗接种前)IgM水平较低(p=0.003)。
  • 低CD19和CD20计数及较短末次BCDT输注至首剂疫苗间隔与抗RBD抗体阴性相关。
  • 年龄、BMI和治疗总时长在血清阳转者与未阳转者间无差异。

临床怎么用

  • 对接受B细胞耗竭治疗的多发性硬化及视神经脊髓炎患者,接种COVID-19 mRNA疫苗后应评估体液免疫反应。
  • 考虑监测CD19/CD20计数及BCDT输注至接种间隔,以识别抗体反应可能受损的患者。

局限性

  • 单中心研究,样本量53人,结果外推需谨慎。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Little is known about COVID-19 mRNA vaccine humoral immune responses in patients with central nervous system autoimmune demyelinating diseases, multiple sclerosis (MS) and neuromyelitis optica (NMO), who are on B-cell depleting therapies (BCDT) and other disease modifying therapies (DMTs). We conducted a single center prospective study to identify the clinical and immunological features associated with vaccine-induced antibody response in 53 participants before and after COVID-19 mRNA vaccination. This is the first report on the anti-spike RBD and anti-nucleocapsid antibody response, along with pre- and post-vaccine absolute lymphocyte counts (ALC) and flow cytometry analysis of CD19 and CD20 lymphocytes in patients with MS and NMO. We tested the hypothesis that patients on BCDT may have impaired COVID-19 vaccine humoral responses. Among patients on BCDT, 36.4% demonstrated a positive antibody response to spike RBD, in comparison to 100% in all other groups such as healthy controls, untreated MS, and patients on non-B cell depleting DMTs (p < 0.0001). Immunological data revealed lower baseline (pre-vaccination) levels of IgM in patients on BCDT (p = 0.003). Low CD19 and CD20 counts and a shorter interval from the last B cell depleting therapy infusion to the first vaccine dose were associated with a negative spike RBD antibody response (non-seroconverter) in patients on BCDT. Age, body mass index (BMI) and total treatment duration did not differ between seroconverters and non-seroconverters.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ali A, Dwyer D, Wu Q, et al. Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine. 2021. PMID: 34483021. doi:10.1016/j.vaccine.2021.08.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。